OverviewSuggest Edit

DarioHealth develops medical device designed to test blood sugar levels via smartphones. Its testing device analyzes consumer health data to personalize treatment and advance medical knowledge, enabling diabetes management and monitoring system to native smart phone application, website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems.

TypePublic
Founded2010
HQNew York, US
Websitemydario.com

Latest Updates

Employees (est.) (Dec 2018)69(+54%)
Revenue (FY, 2018)$7.4 M(+44%)
Share Price (Jun 2019)$0.5 (+15%)

DarioHealth Office Locations

DarioHealth has offices in New York and Caesarea
New York, US (HQ)
142 W 57th St 8th Floor
Caesarea, IL
8 Ha-Tokhen St
Show all (2)

DarioHealth Financials and Metrics

DarioHealth Revenue

DarioHealth's revenue was reported to be $7.39 m in FY, 2018
USD

Revenue (Q2, 2019)

1.7m

Gross profit (Q2, 2019)

326.0k

Gross profit margin (Q2, 2019), %

19.7%

Net income (Q2, 2019)

(5.4m)

EBIT (Q2, 2019)

(5.4m)

Market capitalization (10-Jun-2019)

20.9m

Closing stock price (10-Jun-2019)

0.5

Cash (30-Jun-2019)

8.0m
DarioHealth's current market capitalization is $20.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

51.0k823.0k2.8m5.2m7.4m

Revenue growth, %

1514%241%

Cost of goods sold

2.3m3.4m3.9m5.6m

Gross profit

(2.2m)(561.0k)1.3m1.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

67.0k175.0k273.0k568.0k669.0k728.0k1.0m1.2m1.4m1.8m2.1m1.9m2.2m1.7m

Cost of goods sold

297.0k670.0k826.0k652.0k901.0k850.0k1.1m1.2m1.5m1.4m1.7m1.3m

Gross profit

(230.0k)(102.0k)(157.0k)76.0k106.0k360.0k276.0k552.0k522.0k468.0k558.0k326.0k

Gross profit Margin, %

(343%)(18%)(23%)10%11%30%20%31%25%25%25%20%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.3m1.5m2.7m1.1m3.7m11.0m

Accounts Receivable

99.3m

Inventories

601.0k888.0k1.2m1.4m

Current Assets

2.9m2.1m4.3m2.9m6.0m13.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

4.5m3.8m1.8m4.2m1.9m981.0k1.9m8.3m6.4m3.3m2.8m3.9m6.3m7.0m5.0m11.4m7.0m8.0m

Inventories

22.0k109.0k231.0k207.0k315.0k1.0m1.0m1.1m849.0k717.0k924.0k912.0k1.2m1.0m1.9m1.8m

Current Assets

5.2m4.6m2.4m4.7m2.4m1.6m2.7m10.2m8.1m5.6m5.1m5.9m8.6m8.9m7.3m13.5m9.9m10.8m

PP&E

1.4m1.1m991.0k1.2m935.0k854.0k796.0k682.0k1.0m1.1m856.0k831.0k811.0k828.0k791.0k758.0k732.0k711.0k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(13.9m)(12.9m)(7.1m)(10.9m)(15.7m)(17.8m)

Depreciation and Amortization

839.2k549.0k335.0k387.0k195.0k207.0k

Inventories

(366.0k)(287.0k)(295.0k)(193.0k)

Cash From Operating Activities

(7.6m)(8.6m)(6.3m)(8.4m)(10.6m)(11.5m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

3.5m(3.0m)(6.2m)(9.3m)(1.6m)(3.6m)(5.5m)(1.2m)(3.9m)(5.6m)(5.4m)(850.0k)(12.5m)(2.9m)(8.8m)(12.8m)(5.4m)(10.8m)

Depreciation and Amortization

198.0k358.0k461.0k79.0k163.0k248.0k102.0k191.0k273.0k44.0k101.0k155.0k53.0k101.0k160.0k46.0k93.0k

Inventories

(109.0k)(81.0k)(404.0k)(517.0k)(36.0k)

Cash From Operating Activities

(2.3m)(4.4m)(6.2m)(1.5m)(2.8m)(4.2m)(2.1m)(3.8m)(6.5m)(3.1m)(5.8m)(8.2m)(2.8m)(4.8m)(8.0m)(4.0m)(9.5m)
USDY, 2019

Financial Leverage

2 x
Show all financial metrics

DarioHealth Operating Metrics

FY, 2016

Patents (US)

2
Show all operating metrics

DarioHealth Online and Social Media Presence

Embed Graph

DarioHealth News and Updates

Dance Biopharm Partners With DarioHealth to Expand Access to Digital Therapeutics Platform for Patients With Chronic Diseases

DURHAM, North Carolina and NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Dance Biopharm Holdings, Inc., a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, announced today it has formed a strategic alliance with DarioHealth Corp. "Dario" (Nasdaq:...

DarioHealth Announces Alliance with DigitalHealth.London As Part of the UK Israel Dangoor Health Initiative

NEW YORK and CAESAREA, Israel, Aug. 15, 2019 /PRNewswire/ -- DarioHealth Corp. ("DarioHealth" or "Dario") (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced an alliance with DigitalHealth.London ("DH.L") as part of its UK Israel Dangoor Health Initiative (the...

DarioHealth Reports Results For Second Quarter 2019

NEW YORK and CAESAREA, Israel, Aug. 13, 2019 /PRNewswire/ -- Q2 2019 Revenue of $1.65 million, a 20% decline from Q2 2018 Record 1H 2019 Revenue of $3.89 million, a 2% increase over 1H 2018 Expense shift from D2C to B2B, resulting in a short-term decline in Revenue and an expectation of...

DarioHealth Granted 180-day Extension by Nasdaq to Regain Compliance With bid Price Rule

NEW YORK and CAESAREA, Israel, July 8, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO) today announced that on July 5, 2019, it received notification from Nasdaq that the Company has been granted an additional 180-day compliance period, or until ...

DarioHealth Signs New Functional Medicine Clinic to Its Digital Diabetes Platform

Functional Medicine Center of Fort Collins, in Fort Collins, CO will incorporate Dario's digital diabetes platform to its health and wellness improvement programs NEW YORK, CAESAREA, Israel and FORT COLLINS, Colorado, June 4, 2019 /PRNewswire/ -- Global #digitaltherapeutics innovator...

DarioHealth Corp. Announces Commencement of Public Offering of Common Stock

CAESAREA, Israel, May 21, 2019 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a global digital therapeutics innovator, today announced that it intends to offer and sell shares of common stock (or pre-funded warrants in lieu thereof) in an underwritten...
Show more

DarioHealth Blogs

Follow-up toolbox

Follow-up toolbox Many studies indicate that early treatment of diabetes results in the reduction of potential complications such as heart … Read more

Fasting Blood Sugar

Fasting Blood Sugar As a rule, a fasting blood glucose is taken first thing in the morning before eating or … Read more

In-Range Blood Glucose Levels

In-Range Blood Glucose Levels Hemoglobin A1c (HbA1c or A1c) provides a trend of how high your blood sugar levels have … Read more

Resetting old habits

Resetting old habits Healthy eating habits Most of the carbohydrates you eat is turned into glucose, which is used by … Read more

ADA recommends eating fruits

ADA recommends eating fruits Whole fruit is good for everyone, and for people managing diabetes, it’s no different. Fruit is … Read more

Eat your Fruit!!

Eat your Fruit!! Whole fruit is good for everyone, and for people managing diabetes, it’s no different. Fruit is part … Read more
Show more

DarioHealth Frequently Asked Questions

  • When was DarioHealth founded?

    DarioHealth was founded in 2010.

  • How many employees does DarioHealth have?

    DarioHealth has 69 employees.

  • What is DarioHealth revenue?

    Latest DarioHealth annual revenue is $7.4 m.

  • What is DarioHealth revenue per employee?

    Latest DarioHealth revenue per employee is $107.2 k.

  • Who are DarioHealth competitors?

    Competitors of DarioHealth include Corent Technology, SilverCloud Health and Gobiquity.

  • Where is DarioHealth headquarters?

    DarioHealth headquarters is located at 142 W 57th St 8th Floor, New York.

  • Where are DarioHealth offices?

    DarioHealth has offices in New York and Caesarea.

  • How many offices does DarioHealth have?

    DarioHealth has 2 offices.